ScholarIQanswers from OpenAlex & ORCID
Maciej Krzakowski
ResearcherPublications, citations & collaboration network
Maciej Krzakowski is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Maciej Krzakowski have?
ScholarIQindexed works
Maciej Krzakowski has 574 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Maciej Krzakowski have?
ScholarIQcitation count
Maciej Krzakowski has 19,752 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Maciej Krzakowski?
ScholarIQh-index
Maciej Krzakowski has an h-index of 50 in OpenAlex.
What is the i10-index of Maciej Krzakowski?
ScholarIQi10-index
Maciej Krzakowski has an i10-index of 116 in OpenAlex.
What is the ORCID of Maciej Krzakowski?
ScholarIQorcid
The ORCID for Maciej Krzakowski is on the source record.
What is the OpenAlex record for Maciej Krzakowski?
ScholarIQopenalex
The OpenAlex for Maciej Krzakowski is on the source record.
What are the most-cited papers on Maciej Krzakowski?
ScholarIQmost cited works
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski, Maximilian J. Hochmair, Florian Huemer, György Losonczy, Melissa L. Johnson, Makoto Nishio, Martin Reck, Tony Mok, Sivuonthanh Lam, David S. Shames, Juan Liu, Beiying Ding, Ariel López-Chávez, Fairooz F. Kabbinavar, Wei Lin, Alan Sandler, Stephen V. Liu
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker, Jose R. Pereira, Aleksandra Szczęsna, Joachim von Pawel, Maciej Krzakowski, Rodryg Ramlau, Ihor Vynnychenko, Keunchil Park, Chih-Teng Yu, Valentyn Ganul, Jae-Kyung Roh, Emilio Bajetta, Kenneth J. O’Byrne, Filippo de Marinis, Wilfried Eberhardt, Thomas Goddemeier, Michael Emig, U. Gatzemeier
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Martin Reck, R. Kaiser, Anders Mellemgaard, Jean‐Yves Douillard, С. В. Орлов, Maciej Krzakowski, Joachim von Pawel, Maya Gottfried, Igor Bondarenko, Meilin Liao, Claudia-Nanette Gann, José Barrueco, Birgit Gaschler‐Markefski, Silvia Novello
Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study
Giorgio V. Scagliotti, Vera Hirsh, Salvatore Siena, David H. Henry, Penella J. Woll, Christian Manegold, Philippe Solal‐Céligny, Gladys Rodriguez, Maciej Krzakowski, Nilesh Mehta, Lara Lipton, José Á. García-Sáenz, José Rodrigues Pereira, Kumar Prabhash, Tudor–Eliade Ciuleanu, Vladimir Kanarev, Huei Wang, Arun Balakumaran, Ira Jacobs
Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
Suresh S. Ramalingam, Fiona Blackhall, Maciej Krzakowski, Carlos H. Barrios, Keunchil Park, Isabel Bover, Dae Seog Heo, Rafael Rosell, Denis Talbot, Richard C. Frank, Stephen P. Letrent, Ana Ruiz-Garcı́a, Ian W. Taylor, Jane Liang, Alicyn Campbell, Joseph O’Connell, Michael Boyer